Saldanha Ian J, Dickersin Kay, Wang Xue, Li Tianjing
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
PLoS One. 2014 Oct 16;9(10):e109400. doi: 10.1371/journal.pone.0109400. eCollection 2014.
Choice of outcomes is critical for clinical trialists and systematic reviewers. It is currently unclear how systematic reviewers choose and pre-specify outcomes for systematic reviews. Our objective was to assess the completeness of pre-specification and comparability of outcomes in all Cochrane reviews addressing four common eye conditions.
We examined protocols for all Cochrane reviews as of June 2013 that addressed glaucoma, cataract, age-related macular degeneration (AMD), and diabetic retinopathy (DR). We assessed completeness and comparability for each outcome that was named in ≥ 25% of protocols on those topics. We defined a completely-specified outcome as including information about five elements: domain, specific measurement, specific metric, method of aggregation, and time-points. For each domain, we assessed comparability in how individual elements were specified across protocols.
We identified 57 protocols addressing glaucoma (22), cataract (16), AMD (15), and DR (4). We assessed completeness and comparability for five outcome domains: quality-of-life, visual acuity, intraocular pressure, disease progression, and contrast sensitivity. Overall, these five outcome domains appeared 145 times (instances). Only 15/145 instances (10.3%) were completely specified (all five elements) (median = three elements per outcome). Primary outcomes were more completely specified than non-primary (median = four versus two elements). Quality-of-life was least completely specified (median = one element). Due to largely incomplete outcome pre-specification, conclusive assessment of comparability in outcome usage across the various protocols per condition was not possible.
Outcome pre-specification was largely incomplete; we encourage systematic reviewers to consider all five elements. This will indicate the importance of complete specification to clinical trialists, on whose work systematic reviewers depend, and will indirectly encourage comparable outcome choice to reviewers undertaking related research questions. Complete pre-specification could improve efficiency and reduce bias in data abstraction and analysis during a systematic review. Ultimately, more completely specified and comparable outcomes could make systematic reviews more useful to decision-makers.
结局的选择对于临床试验人员和系统评价者而言至关重要。目前尚不清楚系统评价者如何为系统评价选择并预先设定结局。我们的目标是评估所有针对四种常见眼部疾病的Cochrane系统评价中结局预先设定的完整性以及结局的可比性。
我们审查了截至2013年6月所有针对青光眼、白内障、年龄相关性黄斑变性(AMD)和糖尿病视网膜病变(DR)的Cochrane系统评价方案。我们评估了在这些主题中≥25%的方案中提及的每个结局的完整性和可比性。我们将一个完全设定的结局定义为包括有关五个要素的信息:领域、具体测量方法、具体指标、汇总方法和时间点。对于每个领域,我们评估了各方案中各个要素设定方式的可比性。
我们确定了57个针对青光眼(22个)、白内障(16个)、AMD(15个)和DR(4个)的方案。我们评估了五个结局领域的完整性和可比性:生活质量、视力、眼压、疾病进展和对比敏感度。总体而言,这五个结局领域共出现了145次(实例)。只有15/145个实例(10.3%)是完全设定的(所有五个要素)(每个结局的中位数为三个要素)。主要结局比非主要结局设定得更完整(中位数分别为四个要素和两个要素)。生活质量设定得最不完整(中位数为一个要素)。由于结局预先设定在很大程度上不完整,因此无法对每种疾病的各个方案中结局使用的可比性进行最终评估。
结局预先设定在很大程度上不完整;我们鼓励系统评价者考虑所有五个要素。这将向临床试验人员表明完整设定的重要性,而系统评价者依赖于临床试验人员的工作,并且将间接鼓励进行相关研究问题的评价者选择具有可比性的结局。完整的预先设定可以提高系统评价期间数据提取和分析的效率并减少偏倚。最终,设定更完整且具有可比性的结局可以使系统评价对决策者更有用。